{"nctId":"NCT02143973","briefTitle":"Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus","startDateStruct":{"date":"2014-09"},"conditions":["Uremic Pruritus","Pruritus"],"count":167,"armGroups":[{"label":"nalbuphine HCl ER","type":"EXPERIMENTAL","interventionNames":["Drug: nalbuphine HCl ER"]}],"interventions":[{"name":"nalbuphine HCl ER","otherNames":["nalbuphine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject completed participation in the TR02 study\n* Subject is currently receiving in-center hemodialysis at the time of consent\n\nExclusion Criteria:\n\n* Subject receiving or anticipated to be receiving nocturnal dialysis or home hemodialysis treatment during the study\n* Subject received opiates on a daily basis during the 1 week prior to screening\n* Other than the TR02 Study Drug, Subject received any investigational drug within 4 weeks prior to Screening\n* Subject is a pregnant or lactating female","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"The number of participants reporting at least one TEAE of a particular body system and preferred term are reported (incidence)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":54,"n":167},"commonTop":[]}}}